MedTrace Logo

Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and Hypertension

NCT06256172 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-02-13

No results posted yet for this study

Summary

MEDLINK IS A POCKET-SIZED MEDLINK is a pocket-sized, verbally interactive, programmable medical device that allows physicians to select which medical measurements they would like to take for a specific patient. The Physiological Parameters that can be measured by MEDLINK include, but is not limited to: Electrocardiography (ECG), Blood Pressure, Heart Rate, Blood Glucose, Pulse Rate, Blood Oxygen Saturation (SPO2), Electromyography (EMG) body temperature, and Respiratory Data. MEDLINK is a pocket-sized, verbally interactive, programmable medical device that allows physicians to select which medical measurements they would like to take for a specific patient.

When the patient takes MEDLINK home and switches it on, the device verbally guides the patient to acquire the measurements requested by the his or her physician.

This information is transmitted to the physican's email for medical analysis, check up and/or follow up.

This Study was executed by TWO (2) MEDICAL CONSULTANTS: Dr. Michael Olawuyi ([email protected]) and Dr, Matthew Olawuyi ([email protected])

Conditions

Interventions

DEVICE

Medlink

The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.

Sponsors & Collaborators

  • Olawuyi Racett Nigeria Ltd

    lead INDUSTRY

Principal Investigators

  • Michael Olawuyi, MPH · Olawuyi Racett Nigeria Ltd. United Kingdom RC14668218

  • Matthew Olawuyi, MBBS · Olawuyi Racett Nigeria Ltd. United Kingdom RC14668218

  • Esther Olawuyi, D.Sc. · Olawuyi Racett Nigeria Ltd. United Kingdom RC14668218

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-16
Primary Completion
2023-12-16
Completion
2023-12-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06256172 on ClinicalTrials.gov